(Q80019806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

meta-analysis

0 references

title

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

1 reference

2

Dennis S Chi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Robert E Bristow

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

27 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

1070-1076

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

Identification of prognostic factors in advanced epithelial ovarian carcinoma

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Intervention debulking surgery in advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Interval debulking surgery in advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The potential role of neoadjuvant chemotherapy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The role of induction chemotherapy in inoperable ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Meta-analysis comparing cisplatin total dose intensity and survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Predictive factors for irresectability in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.025

10.1016/J.YGYNO.2006.06.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16875720%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference